Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Public ClinicalTrials.gov record NCT06939036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicentre, Open-label, Phase I/II Study Investigating the Safety, Tolerability, and Preliminary Efficacy of 225Ac-SSO110 in Participants With Extensive Stage Small Cell Lung Cancer (ES-SCLC) or Merkel Cell Carcinoma (MCC) Receiving Standard of Care (SoC)
Study identification
- NCT ID
- NCT06939036
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Ariceum Therapeutics GmbH
- Industry
- Enrollment
- 2 participants
Conditions and interventions
Interventions
- 225Ac-SSO110 + SoC Drug
- Atezolizumab Drug
- Durvalumab Drug
- Avelumab Drug
- Pembrolizumab Drug
- Retifanlimab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2025
- Primary completion
- Dec 30, 2025
- Completion
- Dec 30, 2025
- Last update posted
- Feb 4, 2026
2025
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Biogenix Molecular | Miami | Florida | 33165 | — |
| University of Louisville Health-Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| United Theranostics | Glen Burnie | Maryland | 21061 | — |
| John Theurer Cancer Center at Hackensack UMC | Hackensack | New Jersey | 07601 | — |
| UPMC | Pittsburgh | Pennsylvania | 15219 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06939036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2026 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06939036 live on ClinicalTrials.gov.